NEWSROOM

RespRx

PAOG Cites Research On Hemp Compounds Effectiveness Treating Covid To Advance Pharmaceutical Development

  Sandusky, OH, Jan. 25, 2022 -- McapMediaWire -- PAO Group, Inc. (OTC Pink: PAOG) today cited recently published information on research indicating CBDA and CBGA, compounds found in hemp, “block a critical step in the process the [Covid] virus uses to infect people” (source). “The two compounds were identified during a chemical screening by researchers at the Linus Pauling Institute at Oregon State University. The compounds bind to spike proteins found on the virus and blocked the spike...

read more

PAOG New Pharmaceutical Product Developments Could Generate Rapid Revenue Surge

  Sandusky, OH, Nov. 17, 2021 -- McapMediaWire -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The company has been conducting an in-depth review of its current RespRx CBD pharmaceutical development project with its CRO partner, industry consultants and other...

read more

PAOG Adds Bioidentical Synthetic CBD To Research Pipeline

  Sandusky, OH, Nov. 08, 2021 -- McapMediaWire -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company adding bioidentical synthetic CBD to its overall research initiative. PAOG management highlights the fact that CBD extracted from hemp, as hemp legalization continues to evolve, has certainly brought the multitude of potential health benefits from CBD to light. PAOG has a number of both CBD pharmaceutical and nutraceutical developments under way.  Now, PAOG will add bioidentical...

read more

PAOG Announces Plans To Add New Pharmaceutical Product Developments

  Sandusky, OH, Nov. 05, 2021  -- McapMediaWire -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).   PAOG (resprx.com) The company has been conducting an in-depth review of its current RespRx CBD pharmaceutical development project with its CRO partner, industry...

read more

PAOG Entertains Partnership To Accelerate Development Of CBD Pharmaceutical Treatment For $14 Billion COPD Market

  Sandusky, OH, Oct. 28, 2021 -- McapMediaWire -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company is entertaining a partnership opportunity to accelerate the ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).     The COPD treatment market is anticipated to rise from an estimated $9 billion in 2015 to $14.1 billion in 2025. Last year, PAOG acquired intellectual property derived through research into...

read more

PAOG Releases CBD Nutraceutical 2021 Product Launch Preview Highlighting PURA EVERx Partnership, ALKM Co-Packing and USMJ Distribution

  Sandusky, OH, May 7, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today released a preview of the company’s plan to launch a CBD Nutraceuticals line of products.  PAOG’s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a...

read more

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

  Sandusky, OH, May 5, 2021 – -- PAO Group, Inc. (USOTC: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING...

read more

PAOG 2021 CBD Nutraceutical Sales Rollout Plan Presentation Scheduled This Friday

  Sandusky, OH, May 3, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company’s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT...

read more

PAOG Announces Opportunity To Expand CBD Pharmaceutical Research

  Sandusky, OH, April 13, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today released a management update on the company’s ongoing CBD Pharmaceutical Development Program. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS...

read more

PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021

  Sandusky, OH, April 12, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960...

read more

PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

  Sandusky, OH, April 8, 2021 – --  PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960...

read more

PAOG Targets September 2021 To Introduce CBD Nutraceuticals To Market Co-Packed By ALKM and Marketed Through USMJ

  Sandusky, OH, March 16, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today released details on the company’s nutraceutical developments initiative following last week’s introduction of adding CBD RELAX-RX to existing CBD RespRx developments.  The details today are highlighted by the company’s September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (OTC Pink: ALKM) and product marketing to be conducted by North American Cannabis...

read more

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

  Sandusky, OH, March 8, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). Last...

read more

PAOG Expects To Realize Revenue This Year From New CBD Nutraceuticals

  Sandusky, OH, February 18, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today highlighted the company’s anticipated revenue expected this year from its CBD nutraceutical expansion.  Earlier this week, the company published an online, multimedia presentation detailing the company’s CBD nutraceutical development expansion plans.  The presentation includes details on PAOG’s strategic engagements with Puration, Inc. (OTC Pink: PURA), North American Cannabis Holdings, Inc. (OTC Pink: USMJ) and...

read more

PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation

Sandusky, OH, February 16, 2021 –  -- PAO Group, Inc. (OTC PINK: PAOG) today published an online, multimedia presentation detailing the company’s CBD nutraceutical development expansion plans. The CBD nutraceutical development expansion plans are anticipated to generate revenue beginning this year, in 2021 adding to the company’s previously announced anticipated revenue for 2021. Follow the links below to view the presentation as a Flip book: PAOG Nutraceutical Development Expansion 2021 Or as...

read more

PAOG Targets $18 Billion Anxiety And Depression Treatment Market

  Sandusky, OH, February 11, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced the company’s recently announced CBD nutraceutical development expansion will target the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder...

read more

PAOG Confirms $300,000 Sales Agreement With Cannabis Cultivation Subsidiary

  Sandusky, OH, February 3, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed a $300,000 sales agreement executed by the company’s cannabis cultivation subsidiary. PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020. Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (OTC PINK: PURA). The acquisition was made in conjunction with PAOG’s overall...

read more

PAOG Confirms CBD Nutraceutical Development And Distribution Partners

  Sandusky, OH, February 2, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed its plans to develop and distribute cannabis nutraceuticals with Alkame Holdings, Inc. (OTC PINK: ALKM) and North American Cannabis Holdings, Inc. (OTC PINK: USMJ) as partners. PAOG recently engaged with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing...

read more

PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

  Sandusky, OH, January 14, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year.  The strategic outlook is included in its entirety below: PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly...

read more

PAOG Dividend Update Included In 2021 Cannabis Biopharmaceutical Strategic Update Tomorrow

  Sandusky, OH, January 13, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced the upcoming update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook scheduled for tomorrow, Thursday Jan 14th, 2021, will include an update on the planned PAOG stock dividend to shareholders of Puration, Inc. (OTC PINK: PURA) in conjunction with PAOG’s acquisition of hemp cultivation business from PURA. In 2020, PAOG acquired a hemp cultivation business from...

read more

PAOG Confirms Cannabis Biopharmaceutical Strategic Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

Sandusky, OH, January 12, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented...

read more

PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

  Sandusky, OH – January 11, 2021 – PAO Group, Inc. (OTC PINK: PAOG) today announced an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY).  RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented...

read more

PAOG Confirms Q4 2020 Revenue From Cannabis Asset Acquisition

  Sandusky, OH, January 8, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed that the company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled...

read more

PAOG Takes Major CBD Pharmaceutical Development Step Forward

  Sandusky, OH, January 5, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product. PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts.  PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an...

read more

PAOG Expects To Report First Post Acquisition Revenue In Q4 2020

Sandusky, OH, December 22, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced that the company expects to realize and report in Q3 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled...

read more

PAOG Develops CBD Nutraceutical For $12.7 Billion Market From Patented Extract Process

  Sandusky, OH, December 18, 2020 - - PAO Group, Inc. (OTC US: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020. Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues...

read more

PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution

  Sandusky, OH, December 17, 2020 – -- PAO Group, Inc. (OTC US: PAOG) today announced an engagement with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).     On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC US: KALY) RespRx is a cannabis treatment...

read more

PAOG CEO Discusses 2020 Progress And PURA Dividend On MoneyTV

Sandusky, OH – November 25, 2020 – -- PAO Group, Inc. (OTC: PAOG) today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses the company’s progress in 2020 to include the latest updates on PAOG’s coming one for one dividend of PAOG stock to Puration, Inc. (OTC: PURA) shareholders in conjunction with PAOG’s recent acquisition of PURA’s cannabis cultivation business. https://youtu.be/FzQB462IAws PAOG made two strategic acquisitions this year transitioning the company...

read more

PAOG Publishes First Financial Report Following Two Strategic Acquisitions

Dallas, Texas, November 17, 2020 - - PAO Group, Inc. (OTC US: PAOG) today announced publishing its Q3 2020 report with OTC Markets. This is the first report since making two strategic acquisitions in the course of the third quarter. PAOG transitioned its business direction in the previous quarter making the acquisition of a cannabis extraction technology called RespRx, developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), in addition to acquiring a cannabis cultivation...

read more

PAOG Advances Nutraceutical Development From Its Cannabis Pharmaceutical Research

Sandusky, OH, October 29, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced adding a nutraceutical development pathway to its existing pharmaceutical cannabis drug development strategy.  Last week, PAOG announced a master services agreement with a clinical research organization (CRO) in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  More details on the CRO contract are coming soon.  Now PAOG has...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »